<DOC>
	<DOCNO>NCT01143194</DOCNO>
	<brief_summary>The purpose study investigate effect dietary supplement oréVida™ ( active ingredient basis culinary herb ) administer twice daily acute study improvement vigilance , attention , concentration , memory mood 45 healthy men pre-menopausal woman , age 35-50 year , inclusive . oréVida™ consider dietary supplement , therefore approve drug Food Drug Administration ( FDA ) . It regulate like food . The U.S. Food Drug Administration strictly regulate herb dietary supplement . We claim supplement meant treat ailment .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Double-Blind , Crossover Study Evaluate Effects Three Doses Dietary Supplement oréVida™ Alertness , Attention Concentration Healthy Men Women</brief_title>
	<detailed_description />
	<criteria>Subject male premenopausal female , 3550 year , inclusive . Postmenopausal define history spontaneous amenorrhea period 12 consecutive month six week postsurgical bilateral oophorectomy , without hysterectomy . Subject willing maintain habitual diet usual physical activity pattern throughout study . Subject health condition would prevent him/her fulfil study requirement judge Investigator basis medical history routine laboratory test result . Subject body mass index ( BMI ) ≥20.00 &lt; 30.00 kg/m2 Subject willing refrain consume alcohol 24 h prior test day . Subject willing refrain consume caffeine caffeinecontaining product 12 h prior test day . Subject willing refrain vigorous physical activity 12 h prior test day . Subject nonsmoker . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigator . Subject positive drug screen amphetamine , barbiturate , benzodiazepine , cannabis , cocaine , methamphetamine , methadone , 3,4methylenedioxymethamphetamine , opiates tricyclic antidepressant screen . Subject abnormal laboratory test result clinical significance , include , limited : creatinine ≥1.5 mg/dL , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥1.5X upper limit normal screening . Subject donate 300 mL blood three month prior screen . Subject uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg ) define average blood pressure measure screening . One retest allow separate day prior visit 2 , day 0 subject whose blood pressure exceed either cut point visit 1 . Subject history presence clinically important cardiac , renal , hepatic , endocrine ( include diabetes mellitus ) , pulmonary , biliary , gastrointestinal , pancreatic , neurologic disorder , judgment Investigator , would interfere subject 's ability provide inform consent , comply study protocol ( might confound interpretation study result ) , put subject undue risk . Subject history , judgment Investigator , psychological illness condition interfere subject 's ability understand requirement study . Use sleep aid medication within four day prior test day . Subject history presence cancer prior two year , except nonmelanoma skin cancer . Subject pregnant , plan pregnant study period , lactate , woman childbearing potential unwilling commit use medically approve form contraception throughout study period . The method contraception must record source documentation . Excessive habitual caffeine consumption ( &gt; 300 mg caffeine/d ≥3 cup caffeinated coffee/d ) , follow screen throughout study period . Use psychotropic medication within four week screen throughout study . Use antibiotic sign active systemic infection . Treatment visit reschedule allow subject wash antibiotic least five day prior test visit . Subject exposure nonregistered drug product within 30 day prior screen visit . Use dietary supplement contain following : ginkgo biloba , St. John 's wort , ginseng , gotu kola ( Indian pennywort ) ; daily dos vitamin E ( ≥30 mg/d ) folic acid ( ≥400 ug/d ) ; thiamine , riboflavin , and/or pyridoxine ( ≥2 mg/d ) ; eicosapentaenoic acid ( EPA ) , docosahexaenoic acid combination EPA + DHA ( ≥500 mg/d ) within 2 week screen visit . Recent history ( within 12 month screen visit 1 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) . Subject know allergy sensitivity study product ingredient study product meal provide . The subject unable perform test CDR System train establish acceptable level participation type study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Attention</keyword>
	<keyword>Vigilance</keyword>
	<keyword>Concentration</keyword>
	<keyword>Memory</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>